Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Illinois: - Alton Memorial Hospital — Alton, Illinois
- Advocate Outpatient Center - Aurora — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Illinois: - University of Illinois — Chicago, Illinois
- Elmhurst Memorial Hospital — Elmhurst, Illinois
- Edward Hospital/Cancer Center — Naperville, Illinois
- Edward Hospital/Cancer Center?Plainfield — Plainfield, Illinois
- Memorial Hospital East — Shiloh, Illinois
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Illinois: - Rush - Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Northwestern University — Chicago, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Illinois: - Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
- Rush MD Anderson Cancer Center — Chicago, Illinois
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
- Northwestern Medicine Cancer Center Delnor — Geneva, Illinois
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Illinois: - Associated Urological Specialists - Chicago Ridge — Chicago Ridge, Illinois
- Cancer Care Specialists of Illinois — Decatur, Illinois
- Cancer Care Specialists of Illinois — O'Fallon, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Illinois: - Duly Health and Care — Lisle, Illinois
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Illinois: - Rush University Medical Center-Hematology and Oncology ( Site 0028) — Chicago, Illinois
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063) — Chicago, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that th…
Sponsor: University of Rochester
NCT ID: NCT05838716
Sites in Illinois: - Carle at The Riverfront — Danville, Illinois
- Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
- Carle Physician Group-Effingham — Effingham, Illinois
- Carle Physician Group-Mattoon/Charleston — Mattoon, Illinois
- Cancer Care Center of O'Fallon — O'Fallon, Illinois
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Illinois: - University of Illinois at Chicago ( Site 0105) — Chicago, Illinois
- University of Chicago Medical Center ( Site 0045) — Chicago, Illinois
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Sites in Illinois: - Memorial Hospital East — Shiloh, Illinois
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Illinois: - University of Illinois Chicago — Chicago, Illinois
- Cancer Care Specialists of Illinois — Decatur, Illinois
- Midwestern Regional Medical Center dba City of Hope Chicago — Zion, Illinois
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Illinois: - Research Site — Chicago, Illinois
- Research Site — Chicago Ridge, Illinois
- Research Site — Lake Barrington, Illinois
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in Illinois: - Blessing Hospital — Quincy, Illinois
- Blessing Physician Services — Quincy, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Illinois: - University of Chicago — Chicago, Illinois
- The Cancer Institute of Alexian Brothers — Elk Grove, Illinois
Phase 3 Recruiting Industry
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…
Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in Illinois: - Illinois Cancer Specialists — Niles, Illinois
- Illinois CancerCare PC — Peoria, Illinois
Phase 3 Recruiting Industry
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in Illinois: - UroPartners,LLC — Chicago, Illinois
Phase 3 Recruiting Academic/Other
1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radia…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06274047
Sites in Illinois: - Rush MD Anderson — Chicago, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Illinois: - Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Carle at The Riverfront — Danville, Illinois
- Carle Physician Group-Effingham — Effingham, Illinois
- Illinois CancerCare-Eureka — Eureka, Illinois
Phase 2 Recruiting NIH
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691465
Sites in Illinois: - Northwestern University — Chicago, Illinois
Phase 2 Recruiting Industry
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are ano…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07005154
Sites in Illinois: - Associated Urological Specialists — Chicago Ridge, Illinois
- NorthShore University HealthSystem — Evanston, Illinois
Phase 2 Recruiting Federal
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized pros…
Sponsor: VA Office of Research and Development
NCT ID: NCT05593497
Sites in Illinois: - Jesse Brown VA Medical Center, Chicago, IL — Chicago, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate c…
Sponsor: Northwestern University
NCT ID: NCT06244004
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Northwestern Medicine: Kishwaukee — DeKalb, Illinois
- Northwestern Medicine: Delnor — Geneva, Illinois
- Northwestern University Oak Brook IL453 — Oak Brook, Illinois
- Northwestern Medicine Orland Park — Orland Park, Illinois
Phase 2 Recruiting NIH
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06022822
Sites in Illinois: - Northwestern University — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
Phase 2 Recruiting Academic/Other
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for indiv…
Sponsor: University of Chicago
NCT ID: NCT05726292
Sites in Illinois: - University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Endeavor Health — Evanston, Illinois